Moderna (mRNA Vaccine) for COVID-19: A Leap in Vaccine World

Anita Rani Bhatia; Arpita Saxena; Nitin Tyagi; Peyir Bagra; Paarth Bhatia

doi:10.18502/pbr.v8i1.9391

Anita Rani Bhatia Department of Clinical Biochemistry, Vardhman Mahavir Medical College & Safdarjung Hospital, New Delhi, India.
Arpita Saxena Department of Biochemistry, Vardhman Mahavir Medical College & Safdarjung Hospital, New Delhi, India.
Nitin Tyagi Department of Biochemistry, Vardhman Mahavir Medical College & Safdarjung Hospital, New Delhi, India.
Peyir Bagra Department of Biochemistry, Vardhman Mahavir Medical College & Safdarjung Hospital, New Delhi, India.
Paarth Bhatia Himalayan Institute of Medical Sciences, Jolly Grant, Dehradun, India.

DOI: https://doi.org/10.18502/pbr.v8i1.9391

Keywords: Moderna, Vaccine, COVID-19

Abstract

In December 2019, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) appeared and spread worldwide, triggering a pandemic of respiratory illness. So, there was an urgent need for vaccines worldwide. The mRNA-based vaccines are undergoing an accelerated phase of development during this pandemic. WHO has issued interim guidelines for administering the Moderna mRNA-1273 vaccine against COVID-19 based on advice given by the Strategic Advisory Group of Experts on Immunization (SAGE). The significant future directions for study would be comparing and elucidating the immune processes triggered by mRNA vaccine platforms, developing existing methods focused on these mechanisms, and introducing new clinical trials of these vaccines against additional disease targets.

This study aims to reveal the important role and contribution of the Moderna mRNA-1273 vaccine to COVID-19 vaccinology.

Moderna mRNA-1273 vaccine could be the keystone of modern vaccinology in the context of the COVID-19 pandemic.